In a Phase Ib trial, the combination of PRI-724 and Gemzar (gemcitabine) demonstrated safety and preliminary efficacy in patients with advanced pancreatic adenocarcinoma, resulted in stable disease in 40% (8/20) of the patients, with a median progression-free survival of 2 months, and a median decline of serum S100P level by 49.95% (Journal of Clinical Oncology 34, no. 15_suppl; NCT01764477).

In a preclinical study, the combination of BC2059 and Velcade (bortezomib) worked additively or synergistically in several human multiple myeloma cell lines and primary multiple myeloma cells with activated canonical Wnt signaling in culture (PMID: 28500235).